A promising new therapy for mesothelioma and metastatic cancer, arising from laboratory investigations at the University of Vermont (UVM), is about to enter a Phase I clinical trial. This new approach targets a universal vulnerability in cancer cells that could be exploited therapeutically.
“All tumor cells are very reliant on efficient waste management systems to grow and survive; we were interfering with that,” said Dr. Brian Cunniff, a faculty member in UVM’s Larner College of Medicine’s Pathology and Laboratory Medicine Department, who identified the new therapeutic approach. “The drug takes away the ability of cells to metabolize toxic byproducts, so they essentially choke on their own exhaust,” Dr. Cunniff added.
If you or a loved one has been diagnosed with mesothelioma as a result of exposure to asbestos, contact the experienced attorneys at Nass Cancelliere. For more than 35 years, the Philadelphia-based law firm of NASS CANCELLIERE has represented 4,000 people who have contracted MESOTHELIOMA and other forms of asbestos-related illness. Our attorneys have tried over 1,000 cases throughout Pennsylvania and New Jersey and we have collected over $500 million for our clients. Learn more by calling 215-546-8200 to speak with an attorney or contacting us online.